|
gptkb:NCT03768413
|
Confirmed disability worsening
|
|
gptkb:NCT04150497
|
Change from baseline in pre-bronchodilator FEV1 at Week 24
|
|
gptkb:NCT03887455
|
Change from baseline in AQLQ(S)+12 score
|
|
gptkb:HVTN_505
|
reduction in viral load
|
|
gptkb:NCT02366143
|
Progression-Free Survival
|
|
gptkb:NCT00593450
|
Objective response rate
|
|
gptkb:NCT02366143
|
Overall Survival
|
|
gptkb:NCT01596270
|
All-cause mortality
|
|
gptkb:NCT00593450
|
Duration of response
|
|
gptkb:NCT01327846
|
progression-free survival
|
|
gptkb:NCT01327846
|
duration of response
|
|
gptkb:NCT00239681
|
Response rate
|
|
gptkb:NCT01596270
|
Hospitalization for heart failure
|
|
gptkb:NCT03013101
|
Duration of Response
|
|
gptkb:NCT00239681
|
Overall survival
|
|
gptkb:NCT03013101
|
Overall Survival
|
|
gptkb:NCT03013101
|
Progression-Free Survival
|
|
gptkb:NCT03887455
|
Change from baseline in ACQ-6 score
|
|
gptkb:NCT03887455
|
Change from baseline in pre-bronchodilator FEV1
|
|
gptkb:NCT00593450
|
Overall survival
|